Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CAMX.STthis companyCamurus AB	SEK 737.50	49.6×	8.62×	16.11×	36.15×	-60.8%	93.1%	39.0%	32.5%	17.4%	15.9%	2.0%	0.03×	-3.98×	153.56×	12.09×	0.0%	5	40.92	3	B+
ALZCUR.STAlzeCure Pharma AB	SEK 6.42	-4.26×	6.11×	0×	-3.24×	-92.8%	0.0%	0.0%	0.0%	-144.8%	-139.1%	-17.2%	0.16×	0.94×	-180.85×	2.33×	0.0%	5	15.15	3	B+
BIOA-B.STBioArctic AB	SEK 313.40	26.91×	13.99×	13.76×	19.2×	-226.8%	97.0%	68.4%	51.1%	52.0%	53.8%	5.2%	0.02×	-0.72×	36.1×	4.78×	0.0%	4	21.86	2	C+
EGTX.STEgetis Therapeutics AB (publ)	SEK 11.12	-5.74×	5.81×	31.51×	-5.36×	-144.1%	19.9%	-555.9%	-548.9%	-101.1%	-79.2%	-13.7%	0.27×	0.36×	-15.28×	1.05×	0.0%	5	4.55	1	C-
HNSA.STHansa Biopharma AB (publ)	SEK 41.00	-5.22×	-31.35×	12.55×	-6.25×	-323.4%	62.4%	-234.3%	-240.3%	600.2%	-57.8%	-19.7%	-10.49×	-0.48×	-4.43×	1.94×	0.0%	2	-0.05	2	C
IBT-B.STInfant Bacterial Therapeutics AB (publ)	SEK 72.80	-10.43×	6.46×	0×	-7.87×	-89.1%	0.0%	0.0%	0.0%	-61.9%	-58.8%	-10.6%	0×	2.11×	0×	2.72×	0.0%	2	-1.32	1	D+
Peer median	—	-5.22×	6.11×	12.55×	-5.36×	-144.1%	19.9%	0.0%	0.0%	-61.9%	-58.8%	-13.7%	0.02×	0.36×	-4.43×	2.33×	0.0%	4	4.55	2	—